STOCK TITAN

Moleculin Biotech grants director 4,000 stock options

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Moleculin Biotech, Inc. director Michael D. Cannon received a grant of 4,000 stock options on November 17, 2026, with an exercise price of $6.83 per share. The options vest on the earlier of November 17, 2027, or the date of the company’s next annual meeting, subject to his continued service on the Board on the vesting date. His reported direct option holdings totaled 4,334 after the grant, and the options expire November 17, 2036.

Insider CANNON MICHAEL D
Role Director
Type Security Shares Price Value
Grant/Award Stock Options (right to buy) F2, F1 4,000 -- --
Holdings After Transaction: Stock Options (right to buy) — 4,334 options (Direct)
Holdings Before and After: Stock Options (right to buy), 334 to 4,334 options (Direct)
Footnotes (2)
  1. F1. The options set forth in this table vest on the earlier of November 17, 2027 or the date of the Company's next annual meeting of shareholders, subject to the grantee's continued service on the Company's Board of Directors on the vesting date.
  2. F2. The options were issued in connection with the reporting person's Board of Director service to the Company.
Stock options granted 4,000 options Granted November 17, 2026
Exercise price $6.83 per share Price to exercise the options
Direct option holdings after grant 4,334 options Reported following the November 17, 2026 grant
vesting date financial
"continued service on the Company's Board of Directors on the vesting date"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many stock options did MBRX director Michael D. Cannon receive?

Michael D. Cannon, a director of Moleculin Biotech, received a grant of 4,000 stock options on November 17, 2026, with an exercise price of $6.83 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
CANNON MICHAEL D

(Last)(First)(Middle)
C/O MOLECULIN BIOTECH, INC.
5300 MEMORIAL DR., SUITE 950

(Street)
HOUSTON TEXAS 77007

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Moleculin Biotech, Inc. [ MBRX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/17/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Options (right to buy)$6.8311/17/2026A4,000 (1)11/17/2036Common Stock4,000(2)4,334D
Explanation of Responses:
1. The options set forth in this table vest on the earlier of November 17, 2027 or the date of the Company's next annual meeting of shareholders, subject to the grantee's continued service on the Company's Board of Directors on the vesting date.
2. The options were issued in connection with the reporting person's Board of Director service to the Company.
/s/ Jonathan Foster by Power of Attorney11/19/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading